ClinicalTrials.gg
CompletedNCT04735432ADAPTscUpdated Feb 28, 2023Results posted

Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis

A Phase 3 interventional study of efgartigimod PH20 SC and efgartigimod IV in Generalized Myasthenia Gravis, sponsored by argenx. Completed at 47 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-28.

Sponsored by argenx · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing efgartigimod alfa in Myasthenia Gravis — 11 open to participants now, 14 under way, 7 of them phase 3. efgartigimod alfa · Myasthenia Gravis.

Enrollment
6th of 20
110 · median 55
Started
2021
with 3 others
Phase 3
10 of 20
3 open now
Registered
4th of 20
by date
Lead sponsor
12 of 20
argenx

Among the 20 studies testing efgartigimod alfa in Myasthenia Gravis, this one is the 6th largest by enrollment, is one of 4 that started in 2021, is one of 10 in phase 3, and was the 4th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

11 of the 20 studies testing efgartigimod alfa in Myasthenia Gravis are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About efgartigimod alfa

efgartigimod alfa: first FDA approval 2021 (VYVGART), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing efgartigimod alfa in Myasthenia Gravis, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the Pharmacodynamics (PD), Pharmacokinetics (PK), safety, tolerability, immunogenicity, and clinical efficacy of efgartigimod coformulated with recombinant human hyaluronidase PH20 (rHuPH20) as compared to efgartigimod IV infused in patients with generalized myasthenia gravis (gMG). The study duration is approximately 12 weeks. After screening, patients will be randomized to receive either efgartigimod infusions or efgartigimod PH20 subcutaneously (SC)

Read the detailed description

Main objective of the trial: To demonstrate that the pharmacodynamic (PD) effect of injections of 1000 mg efgartigimod PH20 SC (efgartigimod co-formulated with recombinant humanhyaluronidase PH20 for subcutaneous administration), administered once weekly for 4 administrations, is NI (noninferior) to IV infusions of efgartigimod (efgartigimod formulation for intravenous infusion) at a dose of 10 mg/kg administered once weekly for 4 administrations.

Secondary objectives: To compare the PD effect of efgartigimod PH20 SC and efgartigimod IV over time; To evaluate the pharmacokinetics (PK) of efgartigimod PH20 SC and efgartigimod IV; To evaluate the safety, tolerability, and immunogenicity of efgartigimod PH20 SC and efgartigimod IV; To evaluate the clinical efficacy of efgartigimod PH20 SC and efgartigimod IV.

03

Conditions studied

  • Generalized Myasthenia Gravis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Bullet list of each inclusion criterium:

  1. Must be capable of giving signed , which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  2. At least 18 years of age at the time of signing the informed consent form.
  3. Diagnosed with generalized Myasthenia Gravis (gMG) with confirmed documentation and supported by at least 1 of the following:

    1. History of abnormal neuromuscular transmission demonstrated by single fiber electromyography or repetitive nerve stimulation
    2. History of positive edrophonium chloride test
    3. Demonstrated improvement in Myasthenia Gravis (MG) signs upon treatment with oral acetylcholinesterase (AChE) inhibitors as assessed by the treating physician
  4. Meeting the clinical criteria as defined by the Myasthenia Gravis Foundation of America (MGFA) class II, III, IVa, or IVb

Exclusion criteria

Exclusion Criteria:

Bullet list of each exclusion criterium:

  1. Are pregnant or lactating, or intend to become pregnant during the study or within 90 days after the last dose of Medicinal Product.
  2. Has any of the following medical conditions:

    1. uncontrolled active or chronic bacterial, viral, or fungal infection at screening
    2. Any other known disease that, in the opinion of the investigator, would interfere with an accurate assessment of clinical symptoms of myasthenia gravis or put the participant at undue risk.
    3. History of unless deemed cured by adequate treatment with no evidence of reoccurrence for ≥3 years before the first administration of the IMP. Participants with the following cancers can be included at any time:

      • adequately treated basal cell or squamous cell skin cancer
      • carcinoma in situ of the cervix
      • carcinoma in situ of the breast
      • incidental histological findings of prostate cancer (TNM Classification of Malignant Tumors stage T1a or T1b).
    4. Clinical evidence of other significant serious diseases, or the participant has had a recent major surgery, or who have any other condition that, in the opinion of the investigator, could confound the results of the study or put the participant at undue risk.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    efgartigimod PH20 SC

    Patients receiving efgartigimod PH20 subcutaneous (SC) treatment

    Biological: efgartigimod PH20 SC

  • Experimental
    efgartigimod

    Patients receiving efgartigimod intravenous (IV) treatment

    Biological: efgartigimod IV

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Total IgG Levels at Day 29 (mITT Analysis Set)

    ANCOVA Analysis of Percent Change From Baseline in Total IgG Level at Day 29 (ie, 7 days after the fourth IV or SC administration).

    Time frame: From week 0 to week 4

Secondary outcomes

  1. Percent Change From Baseline in Total IgG Levels Over Time (mITT Analysis Set)

    Total IgG level percent change from baseline over time for the overall population.

    Time frame: From baseline to week 10

  2. Percent Change From Baseline in AChR-Ab Levels Over Time in AChR- Ab Positive Patients (mITT Analysis Set)

    Percent reduction from baseline in AChR-Ab levels over time in AChR-Ab positive patients measured in mITT Analysis Set. Descriptive statistics have been used for this secondary end point.

    Time frame: From baseline to week 10

  3. Percent Change From Baseline in IgG Subtype Levels Over Time (mITT Analysis Set)

    Median (IQR) Percent Change From Baseline for the IgG Subtypes (IgG1, IgG2, IgG3, and IgG4) in the Overall Population. The highest number of patients among all weeks for the analysis is chosen for each arm. Descriptive statistics have been used for this secondary end point.

    Time frame: Baseline to week 10

  4. AUEC of the Percent Change From Baseline in Total IgG Level (mITT Analysis Set)

    AUEC of the percent reduction from baseline total IgG per dosing interval (days 1-8, days 8-15, days 15-22, and days 22-29), days 1-29, days 1-57 and over the entire study (days 1-71). The highest number of patients among all weeks for the analysis is chosen for each arm. Descriptive statistics have been used for this secondary end point.

    Time frame: From baseline to week 10

  5. Еfgartigimod IV and PH20 SC Serum Pharmacokinetic Parameter Ctrough

    Evaluation of observed predose concentration (Ctrough) (after all doses for the IV and SC treatment arms). The analysis will present data from Week 1 to Week 4. Descriptive statistics have been used for this secondary end point.

    Time frame: From Week 1 to Week 4.

  6. Efgartigimod IV Serum Pharmacokinetic Parameter Cmax

    Evaluation of maximum observed concentration (Cmax) (after all doses for the IV treatment arm). The analysis will present data from Baseline to Week 3. Descriptive statistics have been used for this secondary end point.

    Time frame: From Baseline to Week 3

  7. Incidence of ADA Against Efgartigimod (Safety Analysis Set)

    Incidence of antidrug antibodies (ADA) against Efgartigimod in the overall population. ADA analysis is performed with a validated ELISA in a 3-tiered approach (ADA screening analysis, confirmatory analysis and a titration assay). Descriptive statistics have been used for this secondary end point.

    Time frame: From baseline to week 10

  8. Incidence of Antibodies Against rHuPH20 in the SC Treatment Arm (Safety Analysis Set)

    Incidence of antibodies against rHuPH20 in the Efgartigimod PH20 SC Arm. antibody analysis is performed with a validated ELISA in a 3-tiered approach (screening analysis, confirmatory analysis and a titration assay) Descriptive statistics have been used for this secondary end point.

    Time frame: From baseline to week 10

  9. Incidence and Severity of AEs and SAEs (Safety Analysis Set)

    Evaluation of incidence and severity of treatment-emergent adverse events (TEAEs) and incidence of serious AEs (SAEs). Descriptive statistics have been used for this secondary end point.

    Time frame: From baseline to week 10

  10. MG-ADL Responders (ITT Analysis Set)

    Evaluation of number and percentage of Myasthenia Gravis Activities of Daily Living (MG-ADL) responders in the overall population. The MG-ADL is an 8-item patient-reported scale that assesses MG symptoms and their effects on daily activities. It evaluates a participant's capacity to perform different activities in their daily life, including talking, chewing, swallowing, breathing, brushing their teeth, combing their hair, or getting up from a chair. The MG-ADL also assesses double vision and eyelid droop. It is a discrete quantitative variable in which the 8 items are rated by the participant on a scale of 0 to 3. The total score can range from 0 to 24, with higher total scores indicating more impairment. A participant was considered a MG-ADL responder if he/she showed a reduction of at least 2 points from baseline on the MG-ADL score for at least 4 consecutive weeks. Descriptive statistics have been used for this secondary end point.

    Time frame: From baseline to week 10

  11. QMG Responders (ITT Analysis Set)

    Evaluation of number and percentage of Quantitative Myasthenia Gravis (QMG) responders in the overall population (ITT Analysis Set). Descriptive statistics have been used for this secondary end point. One subject in the EFG IV arm had no post-baseline QMG assessment and thus was excluded from the denominator.

    Time frame: From Baseline to Week 10

  12. Change From Baseline in MG-ADL Total Score Over Time (ITT Analysis Set)

    Evaluation of MG-ADL Total Score Change from baseline over time for the overall population (ITT Analysis Set). Descriptive statistics have been used for this secondary end point. The MG-ADL is an 8-item patient-reported scale that assesses MG symptoms and their effects on daily activities. It evaluates a participant's capacity to perform different activities in their daily life, including talking, chewing, swallowing, breathing, brushing their teeth, combing their hair, or getting up from a chair. The MG-ADL also assesses double vision and eyelid droop. It is a discrete quantitative variable in which the 8 items are rated by the participant on a scale of 0 to 3. The total score can range from 0 to 24, with higher total scores indicating more impairment. A participant was considered a MG-ADL responder if he/she showed a reduction of at least 2 points from baseline on the MG-ADL score for at least 4 consecutive weeks.

    Time frame: From baseline to week 10

  13. Change From Baseline in QMG Score Over Time (ITT Analysis Set)

    Evaluation of QMG Total Score change from baseline over time for the overall population (ITT Analysis Set). The QMG (Quantitative Myasthenia Gravis) quantifies disease severity based on impairments of body function and structures as defined by the International Classification of Functioning, Disability and Health. The QMG consists of 13 items that assess ocular, bulbar, and limb function. Six of the 13 items are timed endurance tests measured in seconds. Each item has a possible score from 0 to 3. The total possible score is 39, where higher total scores indicate more severe impairments. It is based on qualitative testing of specific muscle groups to assess limb function. Descriptive statistics have been used for this secondary end point. A participant was considered a QMG responder if he/she showed a reduction of at least 3 points from baseline on the QMG score for at least 4 consecutive weeks.

    Time frame: From baseline to week 10

07

Results

Posted Feb 28, 2023
Limitations and caveats
None reported.

Participant flow

Participant's evaluation of eligibility was performed at screening and confirmed at randomization visit 1. The overall study duration per subject was approximately 12 weeks spanning the study periods - 2 weeks for screening, 3 weeks for treatment, and 7 weeks for follow-up.

Participant flow — Overall Study
MilestoneEfgartigimod PH20 SCEfgartigimod IV
Started5555
Completed5255
Not completed30
Withdrew: Other - due to personal reason10
Withdrew: Adverse event20

Outcome measures

PrimaryPercent Change From Baseline in Total IgG Levels at Day 29 (mITT Analysis Set)

ANCOVA Analysis of Percent Change From Baseline in Total IgG Level at Day 29 (ie, 7 days after the fourth IV or SC administration).

Time frame:
From week 0 to week 4
Reported as:
Least squares mean · percent
Percent Change From Baseline in Total IgG Levels at Day 29 (mITT Analysis Set)
percentEfgartigimod PH20 SCEfgartigimod IV
Percent Change From Baseline in Total IgG Levels at Day 29 (mITT Analysis Set)-66.4 (-68.91 to -63.86)-62.2 (-64.67 to -59.72)
Statistical analysis
  • Efgartigimod PH20 SC vs Efgartigimod IV · ANCOVA · p = < 0.0001 · Ls mean difference: -4.2 · 95% CI -7.73 to -0.66
SecondaryPercent Change From Baseline in Total IgG Levels Over Time (mITT Analysis Set)

Total IgG level percent change from baseline over time for the overall population.

Time frame:
From baseline to week 10
Reported as:
Mean · percent
Percent Change From Baseline in Total IgG Levels Over Time (mITT Analysis Set)
percentEfgartigimod PH20 SCEfgartigimod IV
Week 1-40.1 ± 1.45-39.6 ± 1.51
Week 2-56.9 ± 1.57-55.1 ± 1.85
Week 3-62.2 ± 1.41-59 ± 2
Week 4-64.7 ± 1.95-62.3 ± 1.24
Week 5-57.4 ± 1.7-49.9 ± 2.17
Week 6-44 ± 2.52-38.9 ± 2.24
Week 7-31.2 ± 4.67-25.3 ± 2.78
Week 8-8.9 ± 8.65-14.6 ± 3.13
Week 107.8 ± 7.78-3.1 ± 3.82
SecondaryPercent Change From Baseline in AChR-Ab Levels Over Time in AChR- Ab Positive Patients (mITT Analysis Set)

Percent reduction from baseline in AChR-Ab levels over time in AChR-Ab positive patients measured in mITT Analysis Set. Descriptive statistics have been used for this secondary end point.

Time frame:
From baseline to week 10
Reported as:
Mean · percent
Percent Change From Baseline in AChR-Ab Levels Over Time in AChR- Ab Positive Patients (mITT Analysis Set)
percentEfgartigimod PH20 SCEfgartigimod IV
Week 1-42.5 ± 1.5-43.7 ± 1.55
Week 2-57.4 ± 1.39-55.1 ± 1.52
Week 3-61.8 ± 1.6-59.2 ± 1.66
Week 4-62.2 ± 1.76-59.6 ± 1.74
Week 5-55.3 ± 1.52-47.2 ± 2.98
Week 6-40.4 ± 3.13-29.9 ± 4.61
Week 7-26.7 ± 4.76-15.8 ± 5.63
Week 8-14.5 ± 7.82-7.1 ± 6.02
Week 1013.5 ± 23.1610.3 ± 7.85
SecondaryPercent Change From Baseline in IgG Subtype Levels Over Time (mITT Analysis Set)

Median (IQR) Percent Change From Baseline for the IgG Subtypes (IgG1, IgG2, IgG3, and IgG4) in the Overall Population. The highest number of patients among all weeks for the analysis is chosen for each arm. Descriptive statistics have been used for this secondary end point.

Time frame:
Baseline to week 10
Reported as:
Median · Percent change
Percent Change From Baseline in IgG Subtype Levels Over Time (mITT Analysis Set)
Percent changeEfgartigimod PH20 SCEfgartigimod IV
Percent change from baseline at week 4 IgG1-71 (-79.3 to -56.6)-68.4 (-73 to -61.5)
Percent change from baseline at week 4 IgG2-65.6 (-72.2 to -58.1)-64.5 (-73 to -57.4)
Percent change from baseline at week 4 IgG3-69.6 (-78.3 to -58.4)-64.7 (-76.9 to -59.5)
Percent change from baseline at week 4 IgG4-56.4 (-64.4 to -37.2)-55.5 (-64.2 to -42.1)
SecondaryAUEC of the Percent Change From Baseline in Total IgG Level (mITT Analysis Set)

AUEC of the percent reduction from baseline total IgG per dosing interval (days 1-8, days 8-15, days 15-22, and days 22-29), days 1-29, days 1-57 and over the entire study (days 1-71). The highest number of patients among all weeks for the analysis is chosen for each arm. Descriptive statistics have been used for this secondary end point.

Time frame:
From baseline to week 10
Reported as:
Mean · percent days
AUEC of the Percent Change From Baseline in Total IgG Level (mITT Analysis Set)
percent daysEfgartigimod PH20 SCEfgartigimod IV
Days 1-8 (baseline-week 1)-138.9 ± 5.48-139.1 ± 5.67
Days 8-15 (week 1-week 2)-341.9 ± 9.9-328.3 ± 10.98
Days 15-22 (week 2-week 3)-416.0 ± 12.06-399.8 ± 14.46
Days 22-29 (week 3-week 4)-447.3 ± 9.24-427.0 ± 9.76
Days 1-29 (baseline-week 4)-1332.5 ± 30.78-1311.6 ± 26.35
Days 1-57 (baseline-week 8)-2515.9 ± 96.98-2387.6 ± 77.61
Days 1-71 (baseline-week 10)-2562.9 ± 171.86-2500.3 ± 116.10
SecondaryЕfgartigimod IV and PH20 SC Serum Pharmacokinetic Parameter Ctrough

Evaluation of observed predose concentration (Ctrough) (after all doses for the IV and SC treatment arms). The analysis will present data from Week 1 to Week 4. Descriptive statistics have been used for this secondary end point.

Time frame:
From Week 1 to Week 4.
Reported as:
Mean · μg/mL
Еfgartigimod IV and PH20 SC Serum Pharmacokinetic Parameter Ctrough
μg/mLEfgartigimod PH20 SCEfgartigimod IV
Ctrough week 118.3 ± 8.0516.4 ± 33.0
Ctrough week 221.4 ± 8.3614.0 ± 6.92
Ctrough week 322.5 ± 9.6115.2 ± 8.05
Ctrough week 422.0 ± 8.1214.9 ± 6.43
SecondaryEfgartigimod IV Serum Pharmacokinetic Parameter Cmax

Evaluation of maximum observed concentration (Cmax) (after all doses for the IV treatment arm). The analysis will present data from Baseline to Week 3. Descriptive statistics have been used for this secondary end point.

Time frame:
From Baseline to Week 3
Reported as:
Mean · μg/mL
Efgartigimod IV Serum Pharmacokinetic Parameter Cmax
μg/mLEfgartigimod IV
Cmax Baseline199 ± 62.8
Cmax week 1215 ± 63.0
Cmax week 2211 ± 75.0
Cmax week 3206 ± 59.5
SecondaryIncidence of ADA Against Efgartigimod (Safety Analysis Set)

Incidence of antidrug antibodies (ADA) against Efgartigimod in the overall population. ADA analysis is performed with a validated ELISA in a 3-tiered approach (ADA screening analysis, confirmatory analysis and a titration assay). Descriptive statistics have been used for this secondary end point.

Time frame:
From baseline to week 10
Reported as:
Number · Percent of patients
Incidence of ADA Against Efgartigimod (Safety Analysis Set)
Percent of patientsEfgartigimod PH20 SCEfgartigimod IV
Incidence of ADA Against Efgartigimod (Safety Analysis Set)34.520.0
SecondaryIncidence of Antibodies Against rHuPH20 in the SC Treatment Arm (Safety Analysis Set)

Incidence of antibodies against rHuPH20 in the Efgartigimod PH20 SC Arm. antibody analysis is performed with a validated ELISA in a 3-tiered approach (screening analysis, confirmatory analysis and a titration assay) Descriptive statistics have been used for this secondary end point.

Time frame:
From baseline to week 10
Reported as:
Number · Percent of patients
Incidence of Antibodies Against rHuPH20 in the SC Treatment Arm (Safety Analysis Set)
Percent of patientsEfgartigimod PH20 SC
Incidence of Antibodies Against rHuPH20 in the SC Treatment Arm (Safety Analysis Set)5.5
SecondaryIncidence and Severity of AEs and SAEs (Safety Analysis Set)

Evaluation of incidence and severity of treatment-emergent adverse events (TEAEs) and incidence of serious AEs (SAEs). Descriptive statistics have been used for this secondary end point.

Time frame:
From baseline to week 10
Reported as:
Number · Percent of patients
Incidence and Severity of AEs and SAEs (Safety Analysis Set)
Percent of patientsEfgartigimod PH20 SCEfgartigimod IV
≥1 AE67.350.9
≥1 SAE14.57.3
≥1 Grade 3 or higher AE16.47.3
≥1 AESI18.216.4
≥1 Injection site reaction (localized)38.21.8
≥1 Infusion- or injection-related reaction25.53.6
≥1 Fatal AE00
≥1 Treatment-related AE according to PI43.621.8
≥1 Procedure-related AE according to PI25.53.6
≥1 Treatment-related SAE00
≥1 AE for which the IMP was interrupted1.80
≥1 AE for which the IMP was discontinued3.60
SecondaryMG-ADL Responders (ITT Analysis Set)

Evaluation of number and percentage of Myasthenia Gravis Activities of Daily Living (MG-ADL) responders in the overall population. The MG-ADL is an 8-item patient-reported scale that assesses MG symptoms and their effects on daily activities. It evaluates a participant's capacity to perform different activities in their daily life, including talking, chewing, swallowing, breathing, brushing their teeth, combing their hair, or getting up from a chair. The MG-ADL also assesses double vision and eyelid droop. It is a discrete quantitative variable in which the 8 items are rated by the participant on a scale of 0 to 3. The total score can range from 0 to 24, with higher total scores indicating more impairment. A participant was considered a MG-ADL responder if he/she showed a reduction of at least 2 points from baseline on the MG-ADL score for at least 4 consecutive weeks. Descriptive statistics have been used for this secondary end point.

Time frame:
From baseline to week 10
Reported as:
Number · percent
MG-ADL Responders (ITT Analysis Set)
percentEfgartigimod PH20 SCEfgartigimod IV
MG-ADL Responders (ITT Analysis Set)69.169.1
SecondaryQMG Responders (ITT Analysis Set)

Evaluation of number and percentage of Quantitative Myasthenia Gravis (QMG) responders in the overall population (ITT Analysis Set). Descriptive statistics have been used for this secondary end point. One subject in the EFG IV arm had no post-baseline QMG assessment and thus was excluded from the denominator.

Time frame:
From Baseline to Week 10
Reported as:
Number · percent
QMG Responders (ITT Analysis Set)
percentEfgartigimod PH20 SCEfgartigimod IV
QMG Responders (ITT Analysis Set)65.551.9
SecondaryChange From Baseline in MG-ADL Total Score Over Time (ITT Analysis Set)

Evaluation of MG-ADL Total Score Change from baseline over time for the overall population (ITT Analysis Set). Descriptive statistics have been used for this secondary end point. The MG-ADL is an 8-item patient-reported scale that assesses MG symptoms and their effects on daily activities. It evaluates a participant's capacity to perform different activities in their daily life, including talking, chewing, swallowing, breathing, brushing their teeth, combing their hair, or getting up from a chair. The MG-ADL also assesses double vision and eyelid droop. It is a discrete quantitative variable in which the 8 items are rated by the participant on a scale of 0 to 3. The total score can range from 0 to 24, with higher total scores indicating more impairment. A participant was considered a MG-ADL responder if he/she showed a reduction of at least 2 points from baseline on the MG-ADL score for at least 4 consecutive weeks.

Time frame:
From baseline to week 10
Reported as:
Mean · Total score on a scale
Change From Baseline in MG-ADL Total Score Over Time (ITT Analysis Set)
Total score on a scaleEfgartigimod PH20 SCEfgartigimod IV
Week 1-2.2 ± 0.33-2.0 ± 0.30
Week 2-3.6 ± 0.40-3.2 ± 0.35
Week 3-4.7 ± 0.36-4.3 ± 0.33
Week 4-5.1 ± 0.38-4.7 ± 0.37
Week 5-4.9 ± 0.36-4.3 ± 0.41
Week 6-4.2 ± 0.35-3.7 ± 0.44
Week 7-3.9 ± 0.35-3.6 ± 0.44
Week 8-3.3 ± 0.34-2.9 ± 0.4
Week 10-2.2 ± 0.44-2.1 ± 0.43
SecondaryChange From Baseline in QMG Score Over Time (ITT Analysis Set)

Evaluation of QMG Total Score change from baseline over time for the overall population (ITT Analysis Set). The QMG (Quantitative Myasthenia Gravis) quantifies disease severity based on impairments of body function and structures as defined by the International Classification of Functioning, Disability and Health. The QMG consists of 13 items that assess ocular, bulbar, and limb function. Six of the 13 items are timed endurance tests measured in seconds. Each item has a possible score from 0 to 3. The total possible score is 39, where higher total scores indicate more severe impairments. It is based on qualitative testing of specific muscle groups to assess limb function. Descriptive statistics have been used for this secondary end point. A participant was considered a QMG responder if he/she showed a reduction of at least 3 points from baseline on the QMG score for at least 4 consecutive weeks.

Time frame:
From baseline to week 10
Reported as:
Mean · Total score
Change From Baseline in QMG Score Over Time (ITT Analysis Set)
Total scoreEfgartigimod PH20 SCEfgartigimod IV
Week 1-3 ± 0.48-2 ± 0.44
Week 2-4.3 ± 0.58-3.4 ± 0.44
Week 3-5.7 ± 0.61-4.5 ± 0.5
Week 4-6.1 ± 0.62-5.2 ± 0.52
Week 5-5.9 ± 0.61-5 ± 0.57
Week 6-5.2 ± 0.6-5 ± 0.61
Week 7-3.9 ± 0.61-4.1 ± 0.55
Week 8-3.7 ± 0.66-3.3 ± 0.53
Week 10-2.3 ± 0.6-2.8 ± 0.53

Adverse events

Collected over up to 12 weeks (throughout the treatment period). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Efgartigimod PH20 SC0/55 (0%)8/55 (14.5%)37/55 (67.3%)
Efgartigimod IV0/55 (0%)4/55 (7.3%)23/55 (41.8%)
Most frequent serious events
Most frequent serious events
EventEfgartigimod PH20 SCEfgartigimod IV
Myasthenia gravisNervous system disorders5/551/55
Humerus fractureInjury, poisoning and procedural complications1/550/55
Cardiac failure congestiveCardiac disorders0/551/55
DyspnoeaRespiratory, thoracic and mediastinal disorders1/551/55
Optic neuritisNervous system disorders1/550/55
SyncopeNervous system disorders1/550/55
Chest painGeneral disorders0/551/55
Testicular cystReproductive system and breast disorders0/551/55
CellulitisInfections and infestations1/550/55
Most frequent other events
Showing 10 of 12
Most frequent other events
EventEfgartigimod PH20 SCEfgartigimod IV
Injection site rashGeneral disorders8/550/55
HeadacheNervous system disorders7/557/55
Injection site erythemaGeneral disorders7/550/55
Myasthenia gravisNervous system disorders6/551/55
Injection site pruritusGeneral disorders5/550/55
Injection site bruisingGeneral disorders4/550/55
ContusionInjury, poisoning and procedural complications0/553/55
FallInjury, poisoning and procedural complications1/553/55
FatigueGeneral disorders2/553/55
Injection site painGeneral disorders3/550/55

Baseline characteristics

ITT analysis set: All randomized participants who were exposed to the IMP. mITT analysis set: All randomized participants with a value for total IgG levels at baseline and at least 1 postbaseline time point. Safety analysis set: All randomized participants who were exposed to IMP. PK analysis set: A subset of the safety analysis set with at least 1 post dose PK measurement.

Age, Categorical
Age, Categorical(Participants)Efgartigimod PH20 SCEfgartigimod IVTotal
<=18 years000
Between 18 and 65 years433780
>=65 years121830
Age, Continuous
Age, Continuous(years)Efgartigimod PH20 SCEfgartigimod IVTotal
Median53.0 (19 to 84)59.0 (24 to 83)53.5 (19 to 84)
Sex: Female, Male
Sex: Female, Male(Participants)Efgartigimod PH20 SCEfgartigimod IVTotal
Female313465
Male242145
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Efgartigimod PH20 SCEfgartigimod IVTotal
American Indian or Alaska Native000
Asian448
Native Hawaiian or Other Pacific Islander000
Black or African American000
White5051101
More than one race101
Unknown or Not Reported000
08

Study locations

47 sites
  • Investigator site 2 - US0010032
    Carlsbad, California 92011, United States
  • Investigator Site 41 - US0010004
    Orange, California 92868, United States
  • Investigator site 2 - US0010108
    Boca Raton, Florida 33428, United States
  • Investigator site 1 - US0010110
    Port Charlotte, Florida 33952, United States
  • Investigator Site 27 - US0010006
    Tampa, Florida 41076, United States
  • Investigator Site 47 - US0010113
    Augusta, Georgia 30912, United States
  • Investigator Site 42 - US0010015
    Kansas City, Kansas 66205, United States
  • Investigator Site 11 - US0010111
    Amherst, New York 14226, United States
  • Investigator Site 40 - US0010003
    Chapel Hill, North Carolina 27514, United States
  • Investigator Site 38 - US0010077
    Durham, North Carolina 27710, United States
  • Investigator Site 43 - 0010019
    Cleveland, Ohio 44195, United States
  • Investigator site 4 - US0010008
    Cordova, Tennessee 38018, United States
  • Investigator Site 28 - US0010066
    Austin, Texas 78756, United States
  • Investigator Site 46 - US0010009
    Texas City, Texas 78229, United States
  • Investigator site 5 - BE0320007
    Gent, East-Flanders 9000, Belgium
  • Investigator site 13 - GE9950002
    Tbilisi, 0112, Georgia
  • Investigator site 12 - GE9950001
    Tbilisi, 0114, Georgia
  • Investigator site 14 - GE9950003
    Tbilisi, 0114, Georgia
  • Investigator Site 44 - GE9950004
    Tbilisi, 0160, Georgia
  • Investigator Site 45 - GE9950016
    Tbilisi, 0160, Georgia
  • Investigator Site 30 - DE490006
    Berlin, 10117, Germany
  • Investigator Site 29 - DE490009
    Münster, 48149, Germany
  • Investigator site 15 - HU0360013
    Budapest, 1082, Hungary
  • Investigator Site 16 - HU0360020
    Debrecen, 4032, Hungary
  • Investigator Site 17 - IT0390003
    Milan, 20133, Italy
  • Investigator Site 39 - IT0390008
    Roma, 00189, Italy
  • Investigator Site 31 - JP0810055
    Sapporo, Hokkaido 063-0005, Japan
  • Investigator Site 18 - JP0810002
    Chiba, 260-8677, Japan
  • Investigator site 6 - JPN0810004
    Hanamaki, 025-0082, Japan
  • Investigator Site 33 - JP0810058
    Hiroshima, 0810058, Japan
  • Investigator Site 19 - JP0810007
    Osaka, 565-0871, Japan
  • Investigator Site 34 - JP0810005
    Sendai, 983-8520, Japan
  • Investigator Site 32 - JP0810059
    Tokyo, 143-8541, Japan
  • Investigator Site 20 - JP0810009
    Tokyo, 160-0023, Japan
  • Investigator Site 7 - NL0310001
    Leiden, 2333, Netherlands
  • Investigator Site 21 - PL0480001
    Gdańsk, 80-952, Poland
  • Investigator Site 8 - PL0480007
    Katowice, 40-123, Poland
  • Investigator Site 9 - PL0480024
    Kraków, 31-2002, Poland
  • Investigator Site 22 - PL0480005
    Kraków, 31-505, Poland
  • Investigator Site 23 - PL0480018
    Lublin, 20-093, Poland
  • Investigator Site 24 - PL0480022
    Warsaw, 02-097, Poland
  • Investigator Site 35 - RU0070002
    Novosibirsk, 630087, Russian Federation
  • Investigator Site 36 - RU0070014
    Saint Petersburg, 194354, Russian Federation
  • Investigator Site 37 - ES0340021
    Barcelona, 08035, Spain
  • Investigator Site 26 - ES0340038
    Barcelona, 08041, Spain
  • Investigator Site 25 - ES0340002
    Madrid, 28046, Spain
  • Investigator Site 10 - ES0340039
    Valencia, 46026, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Nov 2021, 8 months.

Results were first posted in Feb 2023, 1 year 3 months after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 8 months is below that.

Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2021
First posted
Feb 3, 2021
StartActual
Feb 5, 2021
Primary completionActual
Nov 2, 2021
CompletionActual
Dec 13, 2021
Results first posted
Feb 28, 2023
Last update
Feb 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04735432
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Feb 3, 2021
Start date
Feb 5, 2021
Primary completion
Nov 2, 2021
Completion
Dec 13, 2021
Results posted
Feb 28, 2023
Last update
Feb 28, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Efgartigimod alfa · Hyaluronidase (human recombinant)

Start the discussion